Cancer

Views & Analysis

Helping HCPs navigate the ever-evolving advanced cancer land...

OPEN Health’s Christine Drewienkiewicz, Sara Black and Annie Rankin on advances in modern oncology and how pharma can help ensure maximum patient benefit

News

Amgen's cancer biosimilars stay on US market as court battle...

Amgen has scored yet another home run in the US courts, this time seeing off a legal challenge from Genentech, which was trying to block it from launching two cut-price cancer biosimilars.

News

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and A

Views & Analysis

COVID-19 and cancer: can pharma stymie the pandemic’s impact...

The COVID-19 pandemic may lead to increased cases of cancer mortality – what can biopharma companies do to help lessen the impact?

News

Gilead to acquire half of cancer biotech Pionyr for $275m

Gilead has announced it is to acquire nearly half of the cancer drug biotech Pionyr, with an exclusive option to acquire the rest of the company as the big pharma continues its expansion in

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

Poseida Therapeutics aims for $115m stock market launch to f...

California biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last week, seeking $115 million in funding for projects including a CAR

Helping HCPs navigate the ever-evolving advanced cancer land...

Amgen's cancer biosimilars stay on US market as court battle...

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

COVID-19 and cancer: can pharma stymie the pandemic’s impact...

Gilead to acquire half of cancer biotech Pionyr for $275m

Poseida Therapeutics aims for $115m stock market launch to f...

Takeda gets first OK for orexin narcolepsy drug, in China

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks